What Is CA 15-3?
CA 15-3 stands for cancer antigen 15-3. It is a substance associated with a protein called MUC1, which is found on the surface of many cells, including breast cells.
A blood test can measure CA 15-3 levels. These may increase in some women with breast cancer, particularly when the disease is advanced.
However, CA 15-3 is not specific to cancer. A higher result does not automatically mean that breast cancer is present.
Why Do Doctors Measure CA 15-3?
CA 15-3 is mainly used in selected patients who have already been diagnosed with breast cancer.
It can provide additional information about how the disease is responding to treatment, particularly when cancer has spread beyond the breast.
Doctors may compare measurements taken over time to identify changes that deserve further investigation.
However, CA 15-3 results cannot replace imaging, medical examinations, or other established methods of monitoring cancer.
What Can Cause Elevated CA 15-3 Levels?
CA 15-3 may increase in breast cancer and certain other malignancies.
Elevated results can also occur in some noncancerous conditions, including liver disease and certain inflammatory disorders.
A single elevated value cannot determine the cause.
Doctors consider the degree of elevation, previous results, symptoms, medical history, and other investigations before deciding whether further testing is necessary.
What Is a Normal CA 15-3 Level?
Reference ranges vary between laboratories and testing methods. Many laboratories use an upper limit of approximately 25–30 units per millilitre.
A result within the reference range does not guarantee that breast cancer is absent.
Some women with breast cancer, particularly at an early stage, have normal CA 15-3 levels.
Likewise, a mildly elevated result does not establish a cancer diagnosis.
What Is the Difference Between CA 15-3 and CA 27.29?
CA 15-3 and CA 27.29 are closely related tumor markers. Both measure substances associated with the MUC1 protein.
They have similar clinical applications, particularly in monitoring selected patients with advanced breast cancer.
Usually, there is no need to measure both markers simultaneously. Their results are not directly interchangeable, and measurements over time are best compared using the same testing method.
Can CA 15-3 Be Part of Proactive Breast Health Care?
A proactive approach considers individual risk factors, family history, symptoms, and previous examination findings.
In selected clinical circumstances, tumor marker testing may provide supplementary information. However, CA 15-3 has not been shown to improve breast cancer detection when routinely used to screen women without symptoms.
It is also not recommended for routine surveillance of asymptomatic women after treatment for early breast cancer.
For early detection, established breast screening methods, particularly mammography, remain much more important. Breast ultrasound or magnetic resonance imaging may be appropriate in selected situations.
